Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression
Author:
Publisher
Wiley
Subject
Urology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-410X.2003.04764.x/fullpdf
Reference16 articles.
1. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell carcinoma of the bladder followed for at least 20 years;Holmäng;J Urol,1995
2. Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology group study;Lamm;J Urol,2000
3. Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized trials;Sylvester;J Urol,2002
4. Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guerin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ;Takashi;Int Urol Nephrol,2002
Cited by 50 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Highlights into historical and current immune interventions for cancer;International Immunopharmacology;2023-04
2. Fremantle protocol: Multicenter clinical outcomes for a pragmatic protocol for intravesical bacillus Calmette–Guerin;Asia-Pacific Journal of Clinical Oncology;2023-01-19
3. Oncologic outcomes of Bacillus Calmette-Guérin therapy in elderly patients with non-muscle-invasive bladder cancer: A meta-analysis;PLOS ONE;2022-05-19
4. Spinal Tuberculosis Secondary to Intravesical Bacille Calmette-Guerin Treatment for Bladder Cancer;Cureus;2021-08-25
5. Bacillus Calmette–Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections;APMIS;2020-01-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3